SBRA Stock Analysis: Buy, Sell, or Hold?

SBRA - Sabra Healthcare REIT, Inc.

REAL ESTATE INVESTMENT TRUSTS
$19.23
-0.21 (-1.08%) ▼
5d: -2.53%
30d: -6.51%
90d: +1.85%
BUY
HIGH Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 04, 2026

Get Alerted When SBRA Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
✅ BUY SIGNAL: SBRA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$29.38
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$18.24
Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: SBRA is currently trading at $19.23, which is considered oversold relative to its 30-day fair value range of $19.78 to $20.74. The stock's valuation (Forward PE: 24.5) is in line with its historical norms (25.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, SBRA is in a strong uptrend. The price is currently testing key support at $19.27. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.92 (+14.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position OVERSOLD
Fair Price Range $19.78 - $20.74
Company Quality Score 57/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 77.1%

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading below Wall St target ($21.92)

Fair Price Analysis

30-Day Fair Range $19.78 - $20.74
Current vs Fair Value OVERSOLD

Support & Resistance Levels

Support Level $19.27
Resistance Level $20.84
Current Trend Strong Uptrend
Technical data as of Mar 31, 2026

Fundamental Context

Forward P/E (Next Year Est.) 24.50
Wall Street Target $21.92 (+14.0%)
Revenue Growth (YoY) 15.8%
Earnings Growth (YoY) -44.7%
Profit Margin 20.1%
Valuation Discount vs History -1.3% cheaper
PE vs Historical 24.5 vs 25.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -1.3% (market-implied from PE analysis)
1-Year Target $18.98 (-1%)
2-Year Target $18.73 (-3%)
3-Year Target $18.49 (-4%)
3-Yr Target (if PE normalizes) (PE: 25→26) $19.25 (+0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 24.5, Growth: 12.9%) $27.71 (+44%)
Base: (SPY PE: 22.4, Growth: 12.9%) $25.28 (+32%)
Bear: (PE: 19.0, Growth: 12.9%) $21.49 (+12%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 30.61 | Current EPS (TTM): $0.64
Bull Case $26.43 (+34%)
Analyst growth 22.7%, PE expands to 33.7
Base Case $24.03 (+22%)
Market implied 22.7%, PE stable at 30.6
Bear Case $13.32 (-32%)
Severe decline -20.0%, PE contracts to 26.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.5 to 25.5
Stabilization Target: $20.02 (+4.1%)
PE Expansion Potential: +4.1%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: March 31, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for SBRA.

Create Free Account

Already have an account? Log In

Top Rated REIT - Healthcare Facilities Stocks

Top-rated stocks in REIT - Healthcare Facilities by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
VTR
Ventas Inc
STRONG BUY
20 analysts
$92 60 HOLD
WELL
Welltower Inc
STRONG BUY
20 analysts
$229 53 HOLD
DOC
Healthpeak Properties Inc
STRONG BUY
20 analysts
$20 54 HOLD
AHR
American Healthcare REIT…
STRONG BUY
9 analysts
$58 59 HOLD
STRW
Strawberry Fields REIT L…
STRONG BUY
7 analysts
$15 55 HOLD

More Analysis for SBRA

SBRA Technical Chart SBRA Price Prediction SBRA Earnings Date SBRA Investment Advisor SBRA Fair Price Analyzer SBRA Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals